{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:05:48Z","timestamp":1784732748673,"version":"3.55.0"},"reference-count":34,"publisher":"Aboutscience Srl","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Grhta"],"abstract":"<jats:p>Introduction: Primary biliary cholangitis (PBC) is a rare, chronic, cholestatic, autoimmune, and disabling liver disease whose treatments are aimed at reducing its progression.The aim was to describe patients with PBC, their healthcare resource utilization (HCRU) and costs on the Italian National Health Service (SSN).Methods: From an Italian administrative healthcare database (~5.5 million inhabitants), called ReS Db, patients with PBC in 2021 (prevalent) were selected by specific codes and described by demographics, comorbidities, one-year HCRU, and health sector costs charged to the SSN. The 3-year treatment pattern was evaluated in a cohort of patients newly diagnosed in 2019 (incident).Results: In 2021, 1375 patients with PBC were identified (prevalence: 28.2\/100,000; females: 74.2%; mean age: 64 \u00b1 15 years). During one-year follow-up of the prevalent cohort: 73.1% received ursodeoxycholic acid (UDCA); 3.0% obeticholic acid (OCA), and 3.4% off-label drugs; 19.9% were hospitalized, mainly for cirrhosis-related conditions; 61.2% were examined by a specialist. The annual mean cost was \u20ac4422\/patient; drugs for PBC, concomitant drugs, and hospitalizations accounted for 12.1%, 31.7%, and 43.6% of total cost, respectively. Among the 40 incident patients, 38 (95%) received UDCA as first-line therapy.Conclusion: The study described the real-world impact of PBC in Italy from the perspective of the SSN and highlightedthe burden and therapeutic needs of patients treated with UDCA.<\/jats:p>","DOI":"10.33393\/grhta.2026.3767","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:39:24Z","timestamp":1784731164000},"page":"192-200","source":"Crossref","is-referenced-by-count":0,"title":["Burden of primary biliary cholangitis on the Italian National Health Service: retrospective analysis from an administrative database"],"prefix":"10.33393","volume":"13","author":[{"given":"Giulia","family":"Ronconi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Dondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9228-5434","authenticated-orcid":false,"given":"Nicola","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Calabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4436-6564","authenticated-orcid":false,"given":"Gioele","family":"Maverna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Acciai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6815-4685","authenticated-orcid":false,"given":"Valentina","family":"Buttiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Vespasiani-Gentilucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5086-0514","authenticated-orcid":false,"given":"Alessio","family":"Gerussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nello","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-8961","authenticated-orcid":false,"given":"Carlo","family":"Piccinni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18642","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"20296","doi-asserted-by":"crossref","unstructured":"Carbone M, Gerussi A, Cardinale V, et al.; AISF Expert Panel. Position paper of the Italian Association for the Study of the Liver (AISF): management and treatment of primary biliary cholangitis. Dig Liver Dis. 2024;56(9):1461-1474. https:\/\/doi.org\/10.1016\/j.dld.2024.05.002 PMID:38902184","DOI":"10.1016\/j.dld.2024.05.002"},{"key":"20297","doi-asserted-by":"crossref","unstructured":"Prince MI, Chetwynd A, Craig WL, et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut. 2004;53(6):865-870. https:\/\/doi.org\/10.1136\/gut.2003.023937 PMID:15138215","DOI":"10.1136\/gut.2003.023937"},{"key":"20298","doi-asserted-by":"crossref","unstructured":"Gazda J, Drazilova S, Janicko M, et al. The epidemiology of primary biliary cholangitis in European countries: a systematic review and meta-analysis. Canadian Journal of Gastroenterology & Hepatology. 2021 https:\/\/doi.org\/10.1155\/2021\/9151525","DOI":"10.1155\/2021\/9151525"},{"key":"20299","doi-asserted-by":"crossref","unstructured":"Hirschfield GM, Beuers U, Corpechot C, et al.; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145-172. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022 PMID:28427765","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"20300","unstructured":"Agenzia Italiana del Farmaco. Ocaliva (acido obeticolico): raccomandazione per la revoca dell\u2019autorizzazione all\u2019immissione in commercio nell\u2019Unione Europea a causa di un beneficio clinico non confermato. Nota Informativa Importante; 2024. Online https:\/\/www.aifa.gov.it\/documents\/20142\/2254729\/2024.07.31_NII_Ocaliva_IT.pdf (Accessed February 2026)"},{"key":"20301","doi-asserted-by":"crossref","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7(6):e0179. https:\/\/doi.org\/10.1097\/HC9.0000000000000179 PMID:37267215","DOI":"10.1097\/HC9.0000000000000179"},{"key":"20302","doi-asserted-by":"crossref","unstructured":"Giannini EG, Pasta A, Calabrese F, et al. Second-line treatment for patients with primary biliary cholangitis: a systematic review with network meta-analysis. Liver Int. 2025;45(1):e16222. https:\/\/doi.org\/10.1111\/liv.16222 PMID:39720853","DOI":"10.1111\/liv.16222"},{"key":"#cr-split#-20303.1","unstructured":"Agenzia Italiana del Farmaco. Determina 30 aprile 2025. Classificazione, ai sensi dell'articolo 12, comma 5, della legge 8 novembre 2012, n. 189, del medicinale per uso umano, a base di seladelpar, \u00abLyvdelzi\u00bb. (Determina n. 607\/2025). (25A02778) (GU Serie Generale n.113 del 17-05-2025). 2025"},{"key":"#cr-split#-20303.2","unstructured":"Online https:\/\/www.gazzettaufficiale.it\/atto\/vediMenuHTML?atto.dataPubblicazioneGazzetta=2025-05-17&atto.codiceRedazionale=25A02778&tipoSerie=serie_generale&tipoVigenza=originario (Accessed February 2026)"},{"key":"20304","doi-asserted-by":"crossref","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, et al.; RESPONSE Study Group. A phase 3 trial of Seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390(9):783-794. https:\/\/doi.org\/10.1056\/NEJMoa2312100 PMID:38381664","DOI":"10.1056\/NEJMoa2312100"},{"key":"20305","doi-asserted-by":"crossref","unstructured":"Kowdley KV, Bowlus CL, Levy C, et al.; ELATIVE Study Investigators' Group; ELATIVE Study Investigators' Group. Efficacy and safety of Elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795-805. https:\/\/doi.org\/10.1056\/NEJMoa2306185 PMID:37962077","DOI":"10.1056\/NEJMoa2306185"},{"key":"20306","unstructured":"European Medicines Agency. Iqirvo. Elafibranor. European Commission decision. 2024. Online https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/iqirvo (Accessed February 2026)"},{"key":"20307","doi-asserted-by":"crossref","unstructured":"Marzioni M, Bassanelli C, Ripellino C, et al. Epidemiology of primary biliary cholangitis in Italy: evidence from a real-world database. Dig Liver Dis. 2019;51(5):724-729. https:\/\/doi.org\/10.1016\/j.dld.2018.11.008 PMID:30584000","DOI":"10.1016\/j.dld.2018.11.008"},{"key":"20308","doi-asserted-by":"crossref","unstructured":"Lleo A, Jepsen P, Morenghi E, et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep. 2016;6(1):25906. https:\/\/doi.org\/10.1038\/srep25906 PMID:27192935","DOI":"10.1038\/srep25906"},{"key":"20309","doi-asserted-by":"crossref","unstructured":"Manno V, Gerussi A, Carbone M, et al. A national hospital-based study of hospitalized patients with primary biliary cholangitis. Hepatol Commun. 2019;3(9):1250-1257. https:\/\/doi.org\/10.1002\/hep4.1407 PMID:31497745","DOI":"10.1002\/hep4.1407"},{"key":"20310","doi-asserted-by":"crossref","unstructured":"Colapietro F, Bertazzoni A, Lleo A. Contemporary epidemiology of primary biliary cholangitis. Clin Liver Dis. 2022;26(4):555-570. https:\/\/doi.org\/10.1016\/j.cld.2022.06.001 PMID:36270716","DOI":"10.1016\/j.cld.2022.06.001"},{"key":"20311","unstructured":"Drummond MFSM, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, 4th ed. Place published: Oxford: Oxford University Press, 2015. ISBN: 9780199665884"},{"key":"20312","unstructured":"ISTAT. Demo Istat. Bilancio demografico e popolazione. Online https:\/\/demo.istat.it\/ (Accessed February 2026)"},{"key":"20313","unstructured":"Norwegian Institute of Public Health - WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index. Online https:\/\/atcddd.fhi.no\/atc_ddd_index\/ (Accessed February 2026)"},{"key":"20314","unstructured":"European Parliament and Council of the European Union. Regulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC. 2014. Online https:\/\/eur-lex.europa.eu\/eli\/reg\/2014\/536\/oj\/eng (Accessed February 2026)"},{"key":"20315","unstructured":"European Parliament and Council of the European Union. Regulation (EU) 2016\/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95\/46\/EC (General Data Protection Regulation). 2016. Online https:\/\/eur-lex.europa.eu\/eli\/reg\/2016\/679\/oj\/eng (Accessed February 2026)"},{"key":"20316","unstructured":"Garante per la protezione dei dati personali. Provvedimento recante le prescrizioni relative al trattamento di categorie particolari di dati, ai sensi dell\u2019art. 21, comma 1 del d.lgs. 10 agosto 2018, n. 101. Online https:\/\/www.garanteprivacy.it\/home\/docweb\/-\/docweb-display\/docweb\/9124510 (Accessed February 2026)"},{"key":"20317","unstructured":"Ministero della Salute. Decreto 30 novembre 2021. Misure volte a facilitare e sostenere la realizzazione degli studi clinici di medicinali senza scopo di lucro e degli studi osservazionali e a disciplinare la cessione di dati e risultati di sperimentazioni senza scopo di lucro a fini registrativi, ai sensi dell'art. 1, comma 1, lettera c), del decreto legislativo 14 maggio 2019, n. 52. (22A01189). Online https:\/\/www.gazzettaufficiale.it\/eli\/id\/2022\/02\/19\/22A01189\/SG (Accessed February 2026)"},{"key":"20318","doi-asserted-by":"crossref","unstructured":"D\u2019Amato D, De Vincentis A, Malinverno F, et al.; Italian PBC Registry and the Club Epatologi Ospedalieri (CLEO)\/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Rep Innov Hepatol. 2021;3(2):100248. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100248 PMID:33681748","DOI":"10.1016\/j.jhepr.2021.100248"},{"key":"20319","doi-asserted-by":"crossref","unstructured":"Terracciani F, De Vincentis A, D'Amato D, et al. Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study. Dig Liver Dis. 2023; 55(S44-S5. https:\/\/doi.org\/10.1016\/j.dld.2023.01.088","DOI":"10.1016\/j.dld.2023.01.088"},{"key":"20320","doi-asserted-by":"crossref","unstructured":"de Veer RC, van Hooff MCB, Werner E, et al.; Dutch PBC Study Group. Incidence and prevalence of primary biliary cholangitis in the Netherlands \u2013 a nationwide cohort study. JHEP Rep Innov Hepatol. 2024;6(8):101132. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101132 PMID:39113899","DOI":"10.1016\/j.jhepr.2024.101132"},{"key":"20321","doi-asserted-by":"crossref","unstructured":"Invernizzi P, Floreani A, Carbone M, et al. Primary biliary cholangitis: advances in management and treatment of the disease. Dig Liver Dis. 2017;49(8):841-846. https:\/\/doi.org\/10.1016\/j.dld.2017.05.001 PMID:28546061","DOI":"10.1016\/j.dld.2017.05.001"},{"key":"20322","doi-asserted-by":"crossref","unstructured":"Rice S, Albani V, Minos D, et al.; UK-PBC Consortium. Effects of primary biliary cholangitis on quality of life and health care costs in the United Kingdom. Clin Gastroenterol Hepatol. 2021;19(4):768-776.e10. https:\/\/doi.org\/10.1016\/j.cgh.2020.06.025 PMID:32562892","DOI":"10.1016\/j.cgh.2020.06.025"},{"key":"20323","doi-asserted-by":"crossref","unstructured":"Gerussi A, Restelli U, Croce D, et al. Cost of illness of primary biliary cholangitis - a population-based study. Dig Liver Dis. 2021;53(9):1167-1170. https:\/\/doi.org\/10.1016\/j.dld.2020.07.029 PMID:32830065","DOI":"10.1016\/j.dld.2020.07.029"},{"key":"20324","doi-asserted-by":"crossref","unstructured":"Samur S, Klebanoff M, Banken R, et al. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology. 2017;65(3):920-928. https:\/\/doi.org\/10.1002\/hep.28932 PMID:27906472","DOI":"10.1002\/hep.28932"},{"key":"#cr-split#-20325.1","unstructured":"Agenzia Italiana del Farmaco. Determina 26 luglio 2017. Classificazione del medicinale per uso umano \u00abOcaliva\u00bb, ai sensi dell'art. 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 1392\/2017). (17A05919) (GU Serie Generale n.196 del 23-08-2017). 2017"},{"key":"#cr-split#-20325.2","unstructured":"Online https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2017-08-23&atto.codiceRedazionale=17A05919&elenco30giorni=true (Accessed February 2026)"},{"key":"20326","doi-asserted-by":"crossref","unstructured":"Kowdley KV, Hirschfield GM, Coombs C, et al. COBALT: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls. Am J Gastroenterol. 2025;120(2):390-400. https:\/\/doi.org\/10.14309\/ajg.0000000000003029 PMID:39140490","DOI":"10.14309\/ajg.0000000000003029"},{"key":"20327","doi-asserted-by":"crossref","unstructured":"Hirschfield GM, Beuers U, Kupcinskas L, et al. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. J Hepatol. 2021;74(2):321-329. https:\/\/doi.org\/10.1016\/j.jhep.2020.09.011 PMID:32950590","DOI":"10.1016\/j.jhep.2020.09.011"}],"container-title":["Global and Regional Health Technology Assessment"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3767\/4619","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3767\/4620","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3767\/4619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:39:29Z","timestamp":1784731169000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/view\/3767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,15]]}},"URL":"https:\/\/doi.org\/10.33393\/grhta.2026.3767","relation":{},"ISSN":["2283-5733","2284-2403"],"issn-type":[{"value":"2283-5733","type":"electronic"},{"value":"2284-2403","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}